Clinical Trial Detail

NCT ID NCT03943342
Title Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Kerry Rogers
Indications

chronic lymphocytic leukemia

Therapies

Ibrutinib

Ibrutinib + Venetoclax

Age Groups: adult senior

No variant requirements are available.